Company: BIVIW
Filing Date: 2025-07-03
Form Type: S-1
Source: 0001520138-25-000198
Chunk: 15

Company: BIOVIE INC.
Filing Date: 2025-07-03
Form: S-1
Chunk 15
---
, 2025 (the “Effective Time”), prior to the effectiveness of the registration statement of which this prospectus
forms a part. When the Reverse Stock Split becomes effective, every ten (10) shares of the Company’s issued and outstanding Common
Stock immediately prior to the Effective Time shall automatically be reclassified into one (1) share of Common Stock, without any change
in the par value per share. The Reverse Stock Split will reduce the number of shares of Common Stock issuable upon the exercise or vesting
of the Company’s outstanding stock options, restricted stock units and warrants in proportion to the ratio of the Reverse Stock
Split and will cause a proportionate increase in the exercise prices of such stock options and warrants. The Reverse Stock Split will
not change the total number of authorized shares of Common Stock.

No fractional shares will be issued as a result
of the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional share in connection with the Reverse
Stock Split will receive one full share of the post-reverse stock split Common Stock in lieu of such fractional share. Commencing on July
7, 2025, trading of our Common Stock will continue on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis.

Other than our historical financial statements
and notes thereto incorporated by reference herein, and except where otherwise noted, all references to our Common Stock presented in
this prospectus have been adjusted to give retroactive effect to the Reverse Stock Split.

Corporate Information

Our principal executive office is located at 680
W. Nye Lane, Suite 201, Carson City, Nevada 89703, and our phone number is (775) 888-3162. Our corporate website address is located at
www.bioviepharma.com. The information on or accessed through our website is not incorporated in this prospectus or the registration
statement of which this prospectus forms a part.

<div align='center'>6</div>

The Offering

| Units offered by us:                                |     | 1,456,310 Units with each Unit consisting of (i) one share of Common                                                                          
 Stock and (ii) one Warrant to purchase one share of Common Stock at an assumed public offering price of $10.30 per Unit, the last             
 reported sale price of our Common Stock as reported on Nasdaq on June 26, 2025.                                                               |
| Pre-funded Units offered by us:                     |     | We are also offering 1,456